GIST RapidScreen Pyro Kit is used for quantitative measurements of mutations in KIT
exon 9 and PDGFRA
exon 18. Detection of mutations in KIT
exon 9 allow the use of the appropriate dose of imatinib and detection of mutations in PDGFRA
exon 18 help to exclude less sensitive or resistant genotypes (1–3).
The kit consists of two assays: one for detecting mutations in KIT
exon 9 and the other for detecting mutations in PDGFRA
exon 18. The two regions are amplified separately by PCR and sequenced through the defined region. Sequences surrounding the defined positions serve as normalization and reference peaks for quantification and quality assessment of the analysis.
The product consists of a PCR primer mix and a sequencing primer for each assay. The primers are delivered in solution. Each vial contains 32 µl of each primer or primer mix.
- The ESMO/European Sarcoma Network Working Group (2012) Gastrointestinal stromal tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23 (Supplement 7), vii49.
- Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) (2010) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: A meta-analysis of 1,640 patients. J. Clin. Oncol. 28, 1247.
- Joensuu, H. (2006) Gastrointestinal stromal tumor (GIST). Ann. Oncol. 17 (Supplement 10), x280.